Company Update: Pfizer Inc (NYSE:PFE) – Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Canc

[Business Wire] – Pfizer Inc. announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine. PROFILE 1014 is a Phase . . . → Read More: Company Update: Pfizer Inc (NYSE:PFE) – Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Canc Similar Articles: Company Update: Pfizer Inc (NYSE:PFE) – Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana® Press, for Women Most in Need in the World’s Poorest Countries Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Completes Acquisition Of InnoPharma